ADAM15 is a member of a family of catalytically active disintegrin membrane metalloproteinases that function as molecular signaling switches, shed membrane bound growth factors and/or cleave and inactivate cell adhesion molecules.
Aberrant metalloproteinase function of ADAM15 may contribute to tumor progression through the release of growth factors or disruption of cell adhesion. In this study, we utilized human bladder cancer tissues and cell lines to evaluate the expression and function of ADAM15 in the progression of human bladder cancer. Examination of genome and transcriptome databases revealed that ADAM15 ranked in the top 5% of amplified genes and its mRNA was significantly overexpressed in invasive and metastatic bladder cancer compared to noninvasive disease. Immunostaining of a bladder tumor tissue array designed to evaluate disease progression revealed increased ADAM15 immunoreactivity associated with increasing cancer stage and exhibited significantly stronger staining in metastatic samples. About half of the invasive tumors and the majority of the metastatic cases exhibited high ADAM15 staining index, while all low grade and noninvasive cases exhibited negative or low staining. The knockdown of ADAM15 mRNA expression significantly inhibited bladder tumor cell migration and reduced the invasive capacity of bladder tumor cells through MatrigelTM and monolayers of vascular endothelium. The knockdown of ADAM15 in a human xenograft model of bladder cancer inhibited tumor growth by 45% compared to controls. Structural modeling of the catalytic domain led to the design of a novel ADAM15-specific sulfonamide inhibitor that demonstrated bioactivity and significantly reduced the viability of bladder cancer cells in vitro and in human bladder cancer xenografts. Taken together, the results revealed an undescribed role of ADAM15 in the invasion of human bladder cancer and suggested that the ADAM15 catalytic domain may represent a viable therapeutic target in patients with advanced disease.
PloS one. 2016 Mar 01*** epublish ***
Guadalupe Lorenzatti Hiles, Amanda Bucheit, John R Rubin, Alexandra Hayward, Angelica L Cates, Kathleen C Day, Layla El-Sawy, L Priya Kunju, Stephanie Daignault, Cheryl T Lee, Monica Liebert, Maha Hussain, Mark L Day
Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Department of Pathology, University of Michigan, Ann Arbor, Michigan, United States of America., Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America., Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America., Division of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, Michigan, United States of America.